Research Yields a 52% Gross Profit For The Company
Los Angeles, CA / ACCESSWIRE / November 17, 2014 / MIT Holding, Inc. (OTCQB: MITD) is pleased to announce new revenue streams with up to 52% gross profits. MIT Holding, through its' facilitators, is acting as a sub-investigator for Melinta Theraputics, who is the main investigator in the Phase 3, multi-center, randomized, double-blind, active controlled study. The purpose of this study is to evaluate the effects of the treatment of patients with complicated bacterial and soft tissue infections.
Walter Drakeford, CEO of MIT Holding stated, "Our test the waters approach to a new revenue stream with these types of margins, are being proven effective with this study. The facilities and employees have met or exceeded all investigative expectations associated with this lucrative and specialized field. This approach has allowed us to streamline our process and provide proof of our capabilities as we look to expand this contract to its maximum commitment, beginning immediately."
Per Clinicaltrials.gov, patients will receive a two to four hour infusion in the blind study at a medical facility. The trial will last for an estimated twelve months and the target enrollment is approximately six hundred and sixty patients (660) treated in the entire trial at multiple facilities throughout the United States, under various sub-investigators. Participants must be 18 years or older and meet the study criteria, you or your doctor may contact the study research staff at ClinicalTrials.gov.
For further information and news about the Company click the following:
Click here for recent news on MITD. - http://www.otcmarkets.com/stock/MITD/news
Click here for current SEC filings for MITD.- http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001367416&owner=exclude&count=40&hidefilings=0
About MIT Holding, Inc.:
MIT Holding and their Agents, Facilitators and contractual obligations in the United States, administer intravenous infusions, contracts ambulatory centers which also sell and rent home medical equipment. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Americas.
For more information, contact Mr. William Nalley, Orsay Groupe, info@orsaygroupe.com, phone 305-515-8077 and/or visit http://www.mitholdingsinc.com/home-2.
Forward-Looking Statements:
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements regarding beliefs, plans, expectations or intentions contain reasonable expectations, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.
Contact:
William Nalley
Info@orsaygroupe.com
305-515-8077
SOURCE: MIT Holding, Inc.